Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesFree Cash FlowNet Cash FlowShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Amortization of Deferred Charges (2020 - 2025)

Historic Amortization of Deferred Charges for Syndax Pharmaceuticals (SNDX) over the last 5 years, with Q3 2025 value amounting to $62000.0.

  • Syndax Pharmaceuticals' Amortization of Deferred Charges changed N/A to $62000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $259000.0, marking a year-over-year change of. This contributed to the annual value of $30000.0 for FY2024, which is N/A changed from last year.
  • Per Syndax Pharmaceuticals' latest filing, its Amortization of Deferred Charges stood at $62000.0 for Q3 2025.
  • In the past 5 years, Syndax Pharmaceuticals' Amortization of Deferred Charges registered a high of $792000.0 during Q3 2022, and its lowest value of -$1.1 million during Q4 2022.
  • In the last 4 years, Syndax Pharmaceuticals' Amortization of Deferred Charges had a median value of $114000.0 in 2021 and averaged $56090.9.
  • Per our database at Business Quant, Syndax Pharmaceuticals' Amortization of Deferred Charges surged by 1272.73% in 2021 and then soared by 53870.97% in 2022.
  • Quarter analysis of 4 years shows Syndax Pharmaceuticals' Amortization of Deferred Charges stood at $124000.0 in 2021, then crashed by 989.52% to -$1.1 million in 2022, then skyrocketed by 102.72% to $30000.0 in 2024, then soared by 106.67% to $62000.0 in 2025.
  • Its Amortization of Deferred Charges was $62000.0 in Q3 2025, compared to $55000.0 in Q2 2025 and $112000.0 in Q1 2025.